Catalent and Novo Holdings
Unlocking Greater Value, Together
Catalent has entered into an agreement to be acquired by Novo Holdings, a global investment firm focused on life sciences. Following the close of the transaction, Catalent will benefit from Novo Holdings’ significant resources, and will be well-positioned to accelerate its strategy to create value for stakeholders, ultimately delivering better outcomes for customers and patients they serve.
Novo Holdings is a global life sciences and healthcare investment firm. In addition to its life sciences investments across subsectors, it has a diversified portfolio of equities, credit, real estate and infrastructure assets.
To continue to build and leverage an ecosystem that enables innovation to deliver better patient outcomes.
As a major pharma services company, Catalent enables its global pharma, biotech, and consumer health partners to optimize their own operations – starting with product development through to product launch and full life-cycle supply.
As announced on February 5, 2024
On May 29, 2024, Catalent stockholders voted to approve the pending transaction
The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions and receipt of required regulatory approvals
At that time, Catalent will become a private company continuing to focus on its mission of enabling the development and supply of better treatments for patients worldwide
In a separate transaction that will occur post-close, Novo Holdings intends to sell three of Catalent’s 50+ global sites located in Anagni, Italy; Bloomington, Indiana USA; and Brussels, Belgium to Novo Nordisk
“Catalent will remain a leading global service provider to the biotech and pharmaceutical industries, following the completion of the transaction with Novo Holdings. Under private ownership, we will benefit from access to additional capital and resources to provide enhanced service for the benefit of customers and patients. Catalent is a Patient First organization with a mission to develop, manufacture and supply products that help people live better and healthier lives – and this will remain our top priority.”
“We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture and supply products that help people live better and healthier lives. With our expertise and track record of investing in high quality life sciences businesses, we believe Catalent is a very good strategic fit. We are excited to support the Company’s stakeholders in the years ahead, especially employees and customers as they work to develop new products to benefit patients. As engaged investors committed to productive relationships with all our partners, we look forward to working with the Catalent team to realise the Company’s full potential.”
